|
Dominantly Inherited Alzheimer''s Network (DIAN): International Network for the Identification, Evaluation, and Follow up of Families with Early Onset of Dominantly Inherited Alzheimer''s Disease
|
Research Initiative
|
FDA
|
NIA
|
This collaboration aims to set up an international network consisting of a consortium of scientific investigators that will have the responsibility to identify, recruit, evaluate, and follow-up individuals from families with early onset dominantly inherited Alzheimer’s Disease [i.e., families with the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) mutations or duplications or others still to be discovered].
|
|
Drug Induced Liver Injury Network (DILIN)
|
Resource Development
|
FDA
|
NIDDK
|
Both a prospective and retrospective database containing cases of drug-induced liver disease, the Drug-Induced Liver Injury Network (DILIN) is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. One of the goals of the DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. The DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Three employees of FDA serve as ad hoc members on the committee overseeing the network activities.
|
|
Early Hearing Detection and Intervention
|
Meeting/ Workshop
|
CDC, HRSA
|
NIDCD
|
This is Federal collaboration program involving NIDCD, CDC, and HRSA. NIDCD collaborates on early identification and diagnosis of hearing loss and intervention services for newborns and infants. HRSA funds awards to states and healthcare providers to screen newborns and young children for hearing loss. CDC funds states to develop data systems to track hearing loss. NIDCD also funds research grants to scientists throughout the US to study early hearing detection and intervention services.
|
|
East Asia Viral Hepatitis and Liver Cancer Consortium
|
Other
|
CDC
|
NCI, NIAID, NIDDK
|
The consortium aims to coordinate and share human, financial, and technical resources to effectively and efficiently address research and public health action needs in the prevention and control of viral hepatitis and liver cancer. This is a trans-HHS collaboration working with the World Health Organization Western Pacific Region Office WHO/WPRO and Ministries of Health of several partner countries.
|
|
Ebola and Infectious Disease Worker Training Program
|
Public Education Campaign
|
CDC
|
NIEHS
|
The Ebola Biosafety and Infectious Disease Response Worker Training Program began June 1, 2016, and will run through May 31, 2019. NIEHS is building federal capacity for biosecurity, bio-preparedness, and rapid response to emerging infectious diseases, including developing an infrastructure of trainers and organizations who can be a resource during emergencies.
|
|
Ebola Clinical Research Response in West Africa
|
Research Initiative
|
CDC, FDA
|
NIAID
|
This is a research collaboration between FDA, NIH, and CDC to respond to the Ebola emergency in West Africa.
|
|
Emergency Preparedness, Medical Countermeasures
|
Resource Development
|
OS
|
NCI
|
NCI provides expertise in radiation biology and radiation oncology to help guide the research and development of medical countermeasures for radiation injury and for biomarkers for assessing injury, dose, and who needs treatment.
|
|
Empowered Communities for Healthier Nation Initiative
|
Other
|
OS
|
NHLBI
|
Review of obesity grant applications for DHHS staff.
|
|
End-stage Renal Disease (ESRD) Collaboration
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NIDDK, NIBIB
|
Participating agencies and patient and physician groups are collaborating to help the medical product development community to understand the challenges and milestones needed to achieve the goal of a successful alternative to dialysis. Research, regulatory, and reimbursement needs for such a product are discussed in phone calls and structured meetings.
|
|
Endocrinologic and Metabolic Drugs Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIAID
|
This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the FDA for drug approval.
|